Hexima (ASX:HXL) Short-Term Debt : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hexima Short-Term Debt?

Hexima's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Hexima's annual Short-Term Debt declined from Jun. 2021 (A$0.03 Mil) to Jun. 2022 (A$0.00 Mil) but then stayed the same from Jun. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil).

Hexima Short-Term Debt Historical Data

The historical data trend for Hexima's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima Short-Term Debt Chart

Hexima Annual Data

Trend

Jun08

Jun09

Jun10

Jun20

Jun21

Jun22

Jun23

Short-Term Debt

Get a 7-Day Free Trial

0.06

0.03

Hexima Semi-Annual Data
	Dec06	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial										0.02	-	-	-	-

Hexima Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Hexima Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Hexima's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hexima (ASX:HXL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.hexima.com.au

Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.